These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36221115)

  • 1. 5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites.
    Shen Y; Ou J; He B; Yang J; Liu H; Wang L; Wang B; Gao L; Yi C; Peng J; Cen X
    Clin Epigenetics; 2022 Oct; 14(1):126. PubMed ID: 36221115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
    Chiu BC; Zhang Z; You Q; Zeng C; Stepniak E; Bracci PM; Yu K; Venkataraman G; Smith SM; He C; Zhang W
    Blood Adv; 2019 Oct; 3(19):2790-2799. PubMed ID: 31570490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
    Chen HY; Zhang WL; Zhang L; Yang P; Li F; Yang ZR; Wang J; Pang M; Hong Y; Yan C; Li W; Liu J; Xu N; Chen L; Xiao XB; Qin Y; He XH; Liu H; Zhu HC; He C; Lin J; Jing HM
    Clin Epigenetics; 2021 Feb; 13(1):33. PubMed ID: 33573703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma.
    Chiu BC; Chen C; You Q; Chiu R; Venkataraman G; Zeng C; Zhang Z; Cui X; Smith SM; He C; Zhang W
    NPJ Genom Med; 2021 Feb; 6(1):11. PubMed ID: 33574286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
    Shen Y; Wang L; Ou J; Wang B; Cen X
    Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
    Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
    Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
    BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA; Olszewski AJ
    Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients.
    Gao P; Lin S; Cai M; Zhu Y; Song Y; Sui Y; Lin J; Liu J; Lu X; Zhong Y; Cui Y; Zhou P
    J Cell Mol Med; 2019 May; 23(5):3530-3537. PubMed ID: 30912288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.
    Chen L; Shen Q; Xu S; Yu H; Pei S; Zhang Y; He X; Wang Q; Li D
    J Alzheimers Dis; 2022; 85(2):573-585. PubMed ID: 34864677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
    Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
    Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLINICAL CHARACTERISTICS OF PRIMARY EXTRANODAL VERSUS NODAL DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE COHORT STUDY IN A CANCER CENTER.
    Candelaria M; Oñate-Ocaña LF; Corona-Herrera J; Barrera-Carmona C; Ponce-Martínez M; Gutiérrez-Hernández O; Avilés-Salas A; Cacho-Díaz B
    Rev Invest Clin; 2019; 71(5):349-358. PubMed ID: 31599881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
    APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
    Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
    J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.